Diluted EPS came in at $-0.02.
Filings will appear here once submitted to SEC EDGAR.
Common questions about Apimeds Pharmaceuticals US, Inc.'s Q4 2024 earnings report.
Apimeds Pharmaceuticals US, Inc. (APUS) reported Q4 2024 earnings on December 31, 2024.
Apimeds Pharmaceuticals US, Inc. reported diluted EPS of $-0.02 for Q4 2024.